Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Xencor Earns $10M Amgen Milestone | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Xencor Earns $10M Amgen Milestone

Amgen submits IND Application for AMG 424

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Xencor, Inc. has earned a $10 million milestone payment from Amgen, triggered by the submission of the IND Application for AMG 424, a humanized T cell–recruiting bispecific antibody targeting CD38 and CD3, which uses Xencor’s Bispecific XmAb Technology.

“XmAb antibody Fc domains continue to enable our partners to create a broad range of drug candidates, in addition to driving our internal programs,” said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. “Our XmAb Fc domains, each providing unique functional improvements to antibodies, open the door to new targets and new biology previously difficult to access. By selectively licensing our XmAb technology, we believe we create value in non-core areas, while we focus on advancing our key internal development programs.”

Amgen licensed the XmAb Bispecific technology for five internal Amgen programs, as well as the Xencor preclinical bispecific T cell engager program directed at CD38 and CD3 for multiple myeloma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics